Are you on the path to weight management using GLP-1 treatments such as Wegovy? Are distancing biscuits and treats proving harder than anticipated? Here on the Bolt Pharmacy blog, we will delve into why sugar cravings may still occur, despite GLP-1 medications designed to support metabolism and control weight. Join us as we untangle the relationship between sugar cravings and Wegovy, providing you with trustworthy insights to support your weight loss journey.

Why Sugar Cravings May Occur While Taking Wegovy

Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities. In the NHS, Wegovy is typically prescribed through specialist weight management services for patients meeting specific NICE criteria (TA875), with treatment duration limits. Whilst the medication is designed to reduce appetite and food intake, some patients report experiencing sugar cravings during treatment.

Several theoretical mechanisms may explain this phenomenon. As Wegovy significantly reduces overall calorie intake and alters eating patterns, the body may initially respond by signalling for quick energy sources, with sugar being the most readily available. This is particularly common during the dose escalation phase when patients are adjusting to reduced food consumption. Additionally, if patients are restricting their diet too severely alongside Wegovy, this might contribute to cravings for high-energy foods.

Psychological factors also play an important role. Many individuals with obesity have established emotional or habitual relationships with sweet foods. When Wegovy reduces physical hunger, the psychological desire for sugar—often linked to stress, boredom, or reward-seeking behaviour—may become more noticeable. Furthermore, as patients lose weight and experience changes in their eating patterns, they may become more aware of specific food desires that were previously masked by general overeating.

It is important to note that clinical trials do not show increased sugar cravings; individual experiences vary. Most patients actually experience reduced cravings for all foods, including sweets. However, understanding the potential reasons behind sugar cravings can help patients and healthcare professionals address them effectively.

How Wegovy Affects Appetite and Food Preferences

Wegovy works by mimicking the action of GLP-1, a naturally occurring hormone released by the intestine after eating. This hormone acts on multiple pathways to regulate appetite and food intake. Semaglutide binds to GLP-1 receptors in the brain, particularly in areas controlling appetite such as the hypothalamus, leading to increased feelings of fullness (satiety) and reduced hunger between meals.

The medication also slows gastric emptying, meaning food remains in the stomach for longer periods. This effect is most pronounced during early treatment and may diminish with continued therapy. This mechanical effect contributes to prolonged satiety after meals and reduces the desire to eat. Clinical trials have demonstrated that patients taking Wegovy typically experience around 15% reduction in body weight on average at 68 weeks in trials (with variation among individuals), largely attributed to decreased calorie intake resulting from these appetite-suppressing effects, as shown in the STEP 1 trial.

Emerging research suggests that GLP-1 receptor agonists may influence food preferences and reward-related eating behaviour. Some observational studies indicate that patients often report reduced interest in high-fat and energy-dense foods. The medication appears to affect the brain's reward pathways, potentially diminishing the pleasure response associated with certain foods, though this evidence is still developing. Many patients describe feeling less interested in foods they previously found irresistible.

However, the effect on sugar cravings specifically is less clear-cut. Whilst some patients report complete loss of interest in sweet foods, others may find that sugar cravings persist or even become more noticeable, particularly if they represent habitual or emotional eating patterns rather than true physiological hunger. The medication primarily addresses homeostatic hunger (eating for energy needs) but may have variable effects on hedonic hunger (eating for pleasure), though this conceptual framework requires further clinical validation. Individual responses depend on factors including baseline eating behaviours, psychological relationship with food, concurrent dietary changes, and metabolic factors.

Managing Sugar Cravings During Wegovy Treatment

If you experience sugar cravings whilst taking Wegovy, several evidence-based strategies can help you manage them effectively without compromising your weight management goals. The key is to address both the physiological and psychological aspects of cravings.

Nutritional strategies form the foundation of craving management:

• Include adequate protein at each meal (often 20-30g per meal is helpful), as protein promotes satiety and helps stabilise blood glucose levels, reducing the likelihood of sugar cravings

• Choose complex carbohydrates such as wholegrain bread, brown rice, oats, and pulses, which provide sustained energy release and prevent the blood sugar fluctuations that can trigger sweet cravings

• Don't restrict calories too severely—Wegovy already reduces appetite, so additional extreme restriction may backfire by intensifying cravings

• Stay well hydrated, as thirst is sometimes misinterpreted as hunger or cravings; aim for 6-8 glasses of water daily as recommended by the NHS

• Eat regular, balanced meals rather than skipping meals, which can lead to energy dips and subsequent sugar cravings

Behavioural approaches are equally important:

• Identify triggers for sugar cravings—keep a food and mood diary to recognise patterns related to stress, boredom, or specific times of day

• Find alternative rewards if you typically use sweet foods for comfort or celebration; consider non-food rewards such as a relaxing bath, reading, or calling a friend

• Practice mindful eating—if you do choose to have something sweet, eat it slowly and without distraction, which often satisfies the craving with a smaller portion

• Keep tempting foods out of immediate reach at home and work, making healthier alternatives more accessible

If you feel you must have something sweet, choose options with nutritional value such as fresh fruit, Greek yoghurt with berries, or a small piece of dark chocolate (70% cocoa or higher). These provide sweetness alongside beneficial nutrients and fibre, which help moderate blood sugar responses.

Your GP can refer you to a registered dietitian for personalised nutritional advice, or to NHS weight management services for additional support with lifestyle changes alongside your Wegovy treatment.

When to Speak to Your GP About Cravings on Wegovy

Whilst occasional sugar cravings during Wegovy treatment are not typically cause for concern, certain situations warrant discussion with your GP or prescribing clinician. Recognising when cravings indicate a more significant issue is important for both treatment success and overall wellbeing.

You should contact your GP if:

• Cravings are intense and persistent, significantly interfering with your daily life or causing distress

• You find yourself binge eating or losing control around sugary foods, which may indicate an underlying eating disorder requiring specialist support (your GP can refer you to appropriate services, or you can contact Beat, the UK eating disorders charity)

• Cravings are accompanied by other symptoms such as shakiness, sweating, confusion, or palpitations, which could suggest hypoglycaemia (low blood sugar), particularly if you have diabetes

• You're not losing weight as expected despite adhering to Wegovy treatment, as this may indicate that cravings are leading to excessive calorie intake that counteracts the medication's effects

• You experience mood changes such as depression, anxiety, or irritability alongside cravings, as these may require separate assessment and management

• You have a history of eating disorders, as Wegovy treatment may require additional psychological support in such cases

Seek urgent medical attention if you experience:

• Severe, persistent upper abdominal pain with or without vomiting, which could indicate pancreatitis or gallbladder disease (known risks with semaglutide)

• Persistent vomiting leading to inability to keep fluids down, which may cause dehydration

Your GP can assess whether your cravings might be related to factors such as inadequate nutrition, blood sugar imbalances, medication interactions, or psychological issues. They may recommend referral to a dietitian for personalised nutritional guidance, particularly if you're struggling to maintain adequate nutrition whilst on Wegovy. In some cases, referral to specialist weight management services or psychological support may be appropriate.

If you have type 2 diabetes and are taking Wegovy alongside other glucose-lowering medications, it's particularly important to discuss cravings with your healthcare team, as they may indicate a need to adjust your diabetes medications to prevent hypoglycaemia. Never stop taking Wegovy without consulting your prescriber, even if you're experiencing cravings, as abrupt discontinuation means you'll lose the appetite-suppressing benefits and may experience rapid weight regain.

Blood Sugar Levels and Wegovy: What You Need to Know

Understanding how Wegovy affects blood glucose (sugar) levels is important, particularly for patients with type 2 diabetes or prediabetes. Semaglutide, the active ingredient in Wegovy, has glucose-dependent effects that influence blood sugar regulation through multiple mechanisms.

How Wegovy affects blood glucose:

Wegovy stimulates insulin secretion from the pancreas in a glucose-dependent manner, meaning it only promotes insulin release when blood glucose levels are elevated, such as after meals. This mechanism significantly reduces the risk of hypoglycaemia (dangerously low blood sugar) compared to some other diabetes medications. The medication also suppresses glucagon secretion—a hormone that raises blood glucose—further contributing to improved glycaemic control.

For patients without diabetes, Wegovy typically has minimal effect on blood glucose levels, which generally remain within the normal range. The medication's primary benefit in this population is weight loss through appetite suppression rather than direct glucose-lowering effects. However, as weight loss progresses, insulin sensitivity naturally improves, which can lead to better blood sugar regulation overall.

For patients with type 2 diabetes, semaglutide provides significant glycaemic benefits. It's important to note that Wegovy (semaglutide 2.4mg) is licensed for weight management, while Ozempic (semaglutide at lower doses) is licensed for diabetes treatment; these products have different licensed indications and doses. Clinical trials have demonstrated reductions in HbA1c (a measure of average blood glucose over three months) with semaglutide treatment, with improvements varying based on baseline levels and dose. This improvement results from both the direct glucose-lowering effects of semaglutide and the indirect benefits of weight loss. NICE guidance (NG28) recognises GLP-1 receptor agonists as effective treatments for type 2 diabetes, particularly in patients with obesity.

Important considerations for blood sugar monitoring:

• If you have diabetes and take Wegovy alongside other glucose-lowering medications (particularly insulin or sulfonylureas), your diabetes medications may need adjustment to prevent hypoglycaemia as your weight decreases and insulin sensitivity improves

• Symptoms of hypoglycaemia include shakiness, sweating, confusion, hunger, irritability, and palpitations—if you experience these, check your blood glucose if possible and consume 15-20g of fast-acting carbohydrate (such as glucose tablets or fruit juice) as advised by NHS guidance

• Regular blood glucose monitoring as advised by your diabetes team is essential during Wegovy treatment

• Eating smaller, more frequent meals with adequate protein can help maintain stable blood glucose levels throughout the day

If you're concerned about blood sugar levels or experiencing symptoms that might be related to glucose fluctuations whilst taking Wegovy, contact your GP or diabetes specialist nurse for assessment and guidance.

Frequently Asked Questions